Jun 20 |
Harrow Provides TRIESENCE® Relaunch Update
|
Jun 6 |
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
|
Jun 5 |
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
|
May 15 |
Harrow to Present at Two Investor Conferences in May
|
May 14 |
Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript
|
May 14 |
Harrow, Inc. 2024 Q1 - Results - Earnings Call Presentation
|
May 13 |
Harrow Health Non-GAAP EPS of -$0.28 misses by $0.07, revenue of $34.59M misses by $2.68M
|
May 13 |
Harrow Announces First Quarter 2024 Financial Results
|
May 13 |
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
|
May 12 |
Harrow Health Q1 2024 Earnings Preview
|